Tricida (NASDAQ:TCDAQ – Get Rating) is one of 986 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it compare to its peers? We will compare Tricida to related companies based on the strength of its risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Risk & Volatility
Tricida has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Tricida's peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Get
Tricida alerts:
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Tricida and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Tricida | 0 | 0 | 0 | 0 | N/A |
| Tricida Competitors | 4168 | 15026 | 41510 | 711 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 120.94%. Given Tricida's peers higher possible upside, analysts clearly believe Tricida has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares Tricida and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio |
| Tricida | N/A | -$176.57 million | 0.00 |
| Tricida Competitors | $1.82 billion | $242.10 million | -3.55 |
Tricida's peers have higher revenue and earnings than Tricida. Tricida is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
40.6% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 35.6% of Tricida shares are owned by insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Tricida and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Tricida | N/A | N/A | -103.81% |
| Tricida Competitors | -3,495.77% | -222.94% | -34.54% |
Summary
Tricida peers beat Tricida on 6 of the 10 factors compared.
About Tricida
(Get Rating)
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.
